Boehringer Ingelheim and Microsoft aim to develop AI-backed digital patient twins
Boehringer Ingelheim and Microsoft announced a strategic collaboration to explore AI‑enabled digital patient twins that model individual patients using clinical and other relevant data. The partners said the work will focus on disease‑progression modelling, predictive outcome modelling, and advanced trial simulation, including synthetic or hybrid control arms that combine existing data with…
Key points
- Boehringer Ingelheim and Microsoft announced a strategic collaboration to explore AI‑enabled digital patient twins for clinical development.
- The joint research will investigate disease‑progression modelling, predictive outcome modelling, and synthetic or hybrid trial control arms, starting with lung health.
- The partnership aims to reduce control‑group sizes, speed evidence generation, and improve trial design while maintaining safety and regulatory compliance.
The joint research will start with lung health and will assess scientific and technical feasibility through modelling, prototyping and evidence generation across multiple disease and therapeutic areas. Both companies stress that scientific quality, patient safety and regulatory requirements must be upheld throughout the effort. Agnes Heftberger, corporate vice‑president and CEO of Microsoft Germany and Austria, said the partnership brings together pharmaceutical expertise with Microsoft’s AI capabilities. Boehringer Ingelheim’s chief medical officer, Dr. Lykke Hinsch Gylvin, added that the aim is to make clinical research more patient‑centric, responsive and efficient.
If successful, the collaboration could reduce the number of patients needed in control groups, speed evidence generation and improve trial design, potentially getting innovative medicines to patients sooner.
Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development
finance.yahoo.com · 21 October 2026
Loading the full article…
This text was published by finance.yahoo.com and written by Boehringer Ingelheim. It is reproduced here with attribution so you can read it in full; the rights remain with the publisher. Read it at the source ↗
The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Research
All →- OpenAI and Google AI models discovered critical PHP flaw affecting millions of websites · 14 src
- Anthropic's Claude autonomously designs protein binders against scorpion neurotoxins · 4 src
- Researchers introduce ViTeX-Bench to test AI video scene-text editing · 1 src
- Minotaur AI matches language model reasoning without a language model · 1 src
- Perplexity and NVIDIA unveil JOLT, a joint teacher‑student RL post‑training method · 1 src
Comments
via GitHub Discussions